These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 28576479

  • 1. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
    Ames MK, Atkins CE, Eriksson A, Hess AM.
    J Vet Cardiol; 2017 Jun; 19(3):218-227. PubMed ID: 28576479
    [Abstract] [Full Text] [Related]

  • 2. Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease.
    Galizzi A, Bagardi M, Stranieri A, Zanaboni AM, Malchiodi D, Borromeo V, Brambilla PG, Locatelli C.
    BMC Vet Res; 2021 Jan 07; 17(1):15. PubMed ID: 33413406
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition.
    Ames MK, Atkins CE, Lantis AC, zum Brunnen J.
    J Renin Angiotensin Aldosterone Syst; 2016 Jan 07; 17(1):1470320316633897. PubMed ID: 27009288
    [Abstract] [Full Text] [Related]

  • 4. The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs.
    Lantis AC, Ames MK, Werre S, Atkins CE.
    J Vet Pharmacol Ther; 2015 Oct 07; 38(5):513-7. PubMed ID: 25771846
    [Abstract] [Full Text] [Related]

  • 5. Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs.
    Lantis AC, Ames MK, Atkins CE, DeFrancesco TC, Keene BW, Werre SR.
    J Vet Pharmacol Ther; 2015 Feb 07; 38(1):65-73. PubMed ID: 25224804
    [Abstract] [Full Text] [Related]

  • 6. Prevalence of aldosterone breakthrough in dogs receiving renin-angiotensin system inhibitors for proteinuric chronic kidney disease.
    Ames MK, Vaden SL, Atkins CE, Palerme JS, Langston CE, Grauer GF, Shropshire S, Bove C, Webb T.
    J Vet Intern Med; 2022 Nov 07; 36(6):2088-2097. PubMed ID: 36350258
    [Abstract] [Full Text] [Related]

  • 7. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST).
    Coffman M, Guillot E, Blondel T, Garelli-Paar C, Feng S, Heartsill S, Atkins CE.
    J Vet Intern Med; 2021 Jul 07; 35(4):1673-1687. PubMed ID: 34028078
    [Abstract] [Full Text] [Related]

  • 8. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J, Hansson K, Karlberg BE, Kvart C, Madej A, Olsson K.
    Am J Vet Res; 1996 Nov 07; 57(11):1645-52. PubMed ID: 8915446
    [Abstract] [Full Text] [Related]

  • 9. Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.
    Yata M, Kooistra HS, Beijerink NJ.
    J Vet Intern Med; 2019 Mar 07; 33(2):462-470. PubMed ID: 30703246
    [Abstract] [Full Text] [Related]

  • 10. Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs.
    Ames MK, Atkins CE, Lee S, Lantis AC, zumBrunnen JR.
    Am J Vet Res; 2015 Dec 07; 76(12):1041-50. PubMed ID: 26618728
    [Abstract] [Full Text] [Related]

  • 11. The classical and alternative circulating renin-angiotensin system in normal dogs and dogs with stage B1 and B2 myxomatous mitral valve disease.
    Hammond HH, Ames MK, Domenig O, Scansen BA, Yang NT, Wilson MD, Sunshine E, Brunk K, Masters A.
    J Vet Intern Med; 2023 Dec 07; 37(3):875-886. PubMed ID: 36951394
    [Abstract] [Full Text] [Related]

  • 12. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
    Borgarelli M, Ferasin L, Lamb K, Bussadori C, Chiavegato D, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2020 Feb 07; 27():34-53. PubMed ID: 32032923
    [Abstract] [Full Text] [Related]

  • 13. Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.
    Adin D, Kurtz K, Atkins C, Papich MG, Vaden S.
    J Vet Intern Med; 2020 Jan 07; 34(1):53-64. PubMed ID: 31769114
    [Abstract] [Full Text] [Related]

  • 14. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J, Lord PF, Höglund K, Ljungvall I, Jöns O, Kvart C, Hansson K.
    J Vet Intern Med; 2013 Jan 07; 27(6):1452-62. PubMed ID: 24128373
    [Abstract] [Full Text] [Related]

  • 15. Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study.
    Lefebvre HP, Ollivier E, Atkins CE, Combes B, Concordet D, Kaltsatos V, Baduel L.
    J Vet Intern Med; 2013 Jan 07; 27(5):1083-91. PubMed ID: 23869534
    [Abstract] [Full Text] [Related]

  • 16. A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
    Newhard DK, Jung S, Winter RL, Duran SH.
    J Vet Intern Med; 2018 Sep 07; 32(5):1555-1563. PubMed ID: 30084228
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
    Wess G, Kresken JG, Wendt R, Gaugele J, Killich M, Keller L, Simak J, Holler P, Bauer A, Küchenhof H, Glaus T.
    J Vet Intern Med; 2020 Nov 07; 34(6):2232-2241. PubMed ID: 32945575
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease.
    Bernay F, Bland JM, Häggström J, Baduel L, Combes B, Lopez A, Kaltsatos V.
    J Vet Intern Med; 2010 Nov 07; 24(2):331-41. PubMed ID: 20102506
    [Abstract] [Full Text] [Related]

  • 19. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study.
    Hezzell MJ, Boswood A, López-Alvarez J, Lötter N, Elliott J.
    J Vet Cardiol; 2017 Aug 07; 19(4):325-338. PubMed ID: 28734620
    [Abstract] [Full Text] [Related]

  • 20. Effect of spironolactone and benazepril on furosemide-induced diuresis and renin-angiotensin-aldosterone system activation in normal dogs.
    Adin D, Atkins C, Wallace G, Klein A.
    J Vet Intern Med; 2021 May 07; 35(3):1245-1254. PubMed ID: 33713485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.